In short
BMS-986442, also known as AGEN1777, is an investigational drug being studied in clinical trials for the treatment of advanced solid tumors and non-small cell lung cancer. This article explores the ongoing research on BMS-986442 in combination with other therapies, providing insights into its potential benefits and the current state of clinical trials.
At a glance
- Drug Name
- BMS-986442 (AGEN1777)
- Study Type
- Phase 1b/2 clinical trial
- Target Conditions
- Advanced solid tumors and non-small cell lung cancer
- Combination Therapy
- With nivolumab or nivolumab and chemotherapy
- Main Objectives
- Safety, tolerability, MTD, MAD, and/or RP2D determination
- Secondary Objectives
- Pharmacokinetics, immunogenicity, preliminary anti-tumor activity
- Key Inclusion Criteria
- Measurable disease (RECIST v1.1), ECOG 0-1, life expectancy ≥3 months
- Key Exclusion Criteria
- Untreated CNS metastases, concurrent malignancy, active autoimmune disease
- Primary Endpoints
- Incidence of AEs, SAEs, DLTs, discontinuations, and death
- Secondary Endpoints
- PK parameters, ADA incidence, anti-tumor efficacy (ORR, DOR, DCR, PFSR)
What is BMS-986442?
BMS-986442, also known as AGEN1777, is a new drug being studied for the treatment of advanced solid tumors and non-small cell lung cancer (NSCLC). It is classified as a targeted antineoplastic antibody, which means it's a type of medication designed to specifically target cancer cells while minimizing damage to healthy cells.
Medical Conditions Targeted
The primary focus of the clinical trials for BMS-986442 is on treating:
- Advanced solid tumors: These are cancers that form solid masses in various parts of the body and have progressed to an advanced stage.
- Non-small cell lung cancer (NSCLC): This is the most common type of lung cancer, accounting for about 80-85% of all lung cancers.
How is it Administered?
BMS-986442 is administered as a solution for injection through intravenous (IV) infusion. This means the medication is given directly into a vein, allowing it to enter the bloodstream quickly and reach cancer cells throughout the body.
Clinical Trial Details
The ongoing clinical trial for BMS-986442 is a Phase 1b/2 study, which aims to evaluate the drug's safety, effectiveness, and optimal dosing. The study is exploring BMS-986442 in combination with other treatments:
- BMS-986442 in combination with nivolumab (another immunotherapy drug)
- BMS-986442 in combination with nivolumab and chemotherapy
The main objectives of the trial are:
- To assess the safety and tolerability of BMS-986442 in these combinations
- To determine the Maximum Tolerated Dose (MTD), Maximum Administered Dose (MAD), and/or Recommended Phase 2 Dose (RP2D)
Eligibility Criteria
To participate in the clinical trial, patients must meet certain criteria. Some key eligibility requirements include:
- Having measurable disease according to specific criteria (RECIST v1.1)
- Having an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1, which indicates the patient is relatively active and able to care for themselves
- Having a life expectancy of at least 3 months
Some conditions that may exclude a patient from participating include:
- Untreated symptomatic brain metastases or cancer that has spread to the protective layers of the brain and spinal cord
- Having another type of cancer that requires treatment or has been active in the past 2 years
- Having an active, known, or suspected autoimmune disease
Potential Benefits and Risks
As with any experimental treatment, there are potential benefits and risks associated with participating in the BMS-986442 clinical trial:
Potential Benefits:
- Access to a new, potentially effective treatment for advanced solid tumors or NSCLC
- Close monitoring by healthcare professionals throughout the trial
- Contributing to the advancement of cancer research
Potential Risks:
- Possible side effects or adverse reactions to the medication
- The treatment may not be effective for every participant
- Time commitment required for study visits and procedures
The trial is closely monitoring for any adverse events (AEs), serious adverse events (SAEs), and other safety concerns. Patients considering participation should discuss the potential risks and benefits with their healthcare provider.